



INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

Clinical Trial Phases: A Guide to Phase I, II, III & IV

Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2025-11-17 · clinical trials · drug development · phase i trial · phase ii trial · phase iii trial · phase iv trial · fda approval process · clinical research

Original article: <https://intuitionlabs.ai/articles/four-phases-clinical-trials>



In this article

1. Clinical Trial Phases: A Guide to Phase I, II, III & IV
 2. Executive Summary
 3. Introduction and Background
 4. Phase I: First-in-Human Studies
 5. Phase II: Dose-Finding and Proof-of-Concept Studies
 6. Phase III: Pivotal Confirmatory Trials
 7. Phase IV: Post-Marketing Surveillance and Beyond
 8. Clinical Trial Pathways and Regulatory Context
 9. Current Trends and Innovations
 10. Case Studies and Real-World Examples
 11. Data and Analysis
 12. Case Studies and Examples
 13. Tables: Comparative Phase Characteristics and Milestones
 14. Implications and Future Directions
 15. Conclusion
-

Clinical Trial Phases: A Guide to Phase I, II, III & IV

Executive Summary

Clinical trials are the scientific cornerstone of modern medicine, providing the evidence base for the safety and efficacy of new drugs and therapies. They are traditionally organized into four successive phases – I, II, III, and IV – each with distinct objectives, designs, and regulatory roles. Phase I trials represent the first human tests of a new investigational drug, focusing primarily on safety, tolerability, and pharmacokinetics in a small group (typically 20–100) of healthy volunteers or sometimes patients (www.fda.gov). Phase II trials expand to several hundred patients with the target disease, aiming to obtain preliminary efficacy and further safety data under controlled conditions (www.fda.gov). Phase III trials are large-scale (hundreds to thousands of subjects) randomized controlled trials that definitively establish clinical efficacy and monitor infrequent adverse events; these studies form the core of **data for regulatory approval** (www.fda.gov). Following market authorization, Phase IV (post-marketing) studies collect **real-world data** on long-term safety, effectiveness, and off-label use in broader populations (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Despite rigorous testing, drug development has a high attrition rate. Only a small fraction of compounds that enter human trials ultimately gain approval. Recent analyses indicate overall success rates (Phase I through approval) on the order of 5–10% for industry-sponsored programs, with a 2025 dynamic analysis of over 20,000 clinical development programs confirming the overall rate has stabilized around 5% (pmc.ncbi.nlm.nih.gov) ([Nature Communications](#)). Leading pharmaceutical companies achieve an average likelihood of approval of approximately 14.3%, ranging from 8% to 23% ([ScienceDirect](#)). In practical terms,

roughly one in ten to twenty investigational drugs that begin Phase I will eventually receive FDA approval. Much of the attrition occurs in Phase II: many candidate drugs that show safety in early trials fail to demonstrate adequate efficacy or acceptable safety in patients. These statistics underscore the challenge of translating preclinical promise into clinical benefit.

The four-phase model has evolved over decades in response to scientific, ethical, and regulatory developments. Its history spans from early antiseptic trials and the first randomized controlled trials of the mid-20th century, through the post–Thalidomide regulatory overhaul of the 1960s, to the modern era of globalized, highly regulated drug development. Regulatory agencies such as the U.S. FDA and EMA provide formal definitions and guidance for each phase, shaping trial design and execution. For example, the FDA defines Phase I studies as “the initial introduction of an investigational new drug into humans...designed to determine” metabolic action, dose, and side effects (www.fda.gov), while Phase IV studies are explicitly tied to post-approval surveillance and market experience (pmc.ncbi.nlm.nih.gov).

This report provides an in-depth exploration of each clinical trial phase from multiple perspectives. It examines the scientific aims, methodological features, and typical scale of Phase I–III trials, and the role of Phase IV research in the life cycle of a medicine. It analyzes current data on trial success rates, sample sizes, and timelines. Ethical considerations and regulatory frameworks for each phase are discussed, as are emerging trends such as adaptive and seamless trial designs that blur traditional phase boundaries. Detailed case studies illustrate key points: for instance, first-in-human trials in oncology often enroll advanced cancer patients rather than healthy volunteers, and the TGN1412 Phase I trial informed subsequent approaches to first-in-human dosing. Another case highlights how overlapping trials expedited COVID-19 vaccine development under Emergency Use protocols. The report also examines specialized topics like conditional approvals, [orphan drugs](#), and global harmonization of trial standards. Data tables summarize stage-specific attributes (objectives, population, size, endpoints) and major regulatory milestones.

By integrating historical context, quantitative evidence, and expert insights, this comprehensive review elucidates how the four phases of clinical trials function individually and together. It highlights the critical importance of each phase in ensuring that new therapies are both effective and safe. Finally, it considers future directions: innovations such as digital health data, patient-reported outcomes, and platform trials promise to make clinical research faster and more inclusive, but also require careful methodological adaptation. The conclusion synthesizes the implications for drug developers, regulators, healthcare providers, and patients. All claims and data herein are supported by authoritative sources from regulators, peer-reviewed journals, and industry analyses (www.fda.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Introduction and Background

Randomized controlled clinical trials (RCTs) have roots in antiquity (e.g. James Lind’s scurvy trial in 1747) and were formalized in modern medicine during the 20th century (for example, the 1948 streptomycin trial for tuberculosis) (pmc.ncbi.nlm.nih.gov). However, the structured system of four sequential phases for drug trials emerged as regulatory scrutiny increased. In the U.S., key legislation shaped this system. The 1938 Federal Food, Drug, and Cosmetic Act first required proof of safety before marketing; the 1962 Kefauver–Harris Amendments then mandated substantial evidence of efficacy through “adequate and well-controlled investigations” – essentially embedding Phase III-scale RCTs into law (pmc.ncbi.nlm.nih.gov). Worldwide,

harmonization efforts (e.g. the [International Council for Harmonisation, ICH](#)) have since standardized requirements. For example, [ICH E6 \(Good Clinical Practice\)](#), now in its R3 revision finalized in January 2025 and implemented across regions through 2025–2026, guides the design/conduct of trials across all phases, ensuring ethical principles and quality standards in human research (www.ema.europa.eu).

Under the predominant model, clinical development of a new drug proceeds through **four phases**:

- **Phase I:** First-in-human trials (FIH) for safety and dose-finding. Small cohorts (often 20–100 subjects) are given single or escalating doses. Traditionally performed in healthy volunteers (unless the drug is too toxic, e.g. chemotherapy in cancer patients). The focus is on adverse effects, pharmacokinetics (absorption, metabolism, etc.), and identifying a safe dose range (www.fda.gov).
- **Phase II:** Exploratory efficacy trials in patients. Several hundred subjects with the target disease receive the investigational drug (and often comparator arms or placebo). Primary goals include preliminary assessment of clinical efficacy signals and continued safety/tolerability evaluation (www.fda.gov), often across multiple dose levels or doses. Phase II may be split into IIa (pilot efficacy) and IIb (dose-ranging) in some terminologies.
- **Phase III:** Confirmatory trials to establish definitive efficacy and safety for regulatory approval. Large sample sizes (hundreds or thousands) allow statistical power to detect treatment effects and rarer side effects (www.fda.gov). These are typically randomized, controlled, multicenter trials. Success in Phase III is needed to file a New Drug Application (NDA) or Biologics License Application (BLA) with the FDA (or equivalent submissions abroad).
- **Phase IV:** Post-approval (post-marketing) studies. These monitor the drug's performance in real-world clinical practice. This phase can include well-organized observational studies, registries, long-term safety monitoring, and trials in new populations or indications. Importantly, Phase IV captures rare adverse events and long-term outcomes that may not be evident in pre-approval trials (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For example, Phase IV findings may lead to updated communications, labeling, or market status.

The four-phase structure is not an immutable law; overlap and exceptions occur. For instance, adaptive or “seamless” trial designs combine phases (e.g. an open-label dose-escalation Phase I/IIa in oncology). Accelerated pathways (Fast Track, Breakthrough, etc.) can compress transitions between phases for serious diseases (pmc.ncbi.nlm.nih.gov). Nevertheless, the Phase I–IV language remains the lingua franca of clinical research, reflecting increasing scale and maturity of evidence.

Table 1 (below) summarizes core features of each phase. Key points include the shift from safety-focused, healthy-subject trials in Phase I to efficacy-focused, patient-centered trials in Phases II/III, then to broad surveillance in Phase IV (www.fda.gov) (pmc.ncbi.nlm.nih.gov).

Phase	Typical Participants	Primary Objectives	Typical Size (Subjects)	Key Endpoints / Outcomes
I	Healthy volunteers (or very ill patients in oncology/toxo cases) (www.fda.gov)	Assess safety, tolerability, pharmacokinetics/dynamics, maximum tolerated dose (www.fda.gov)	~20–100 (dose-escalation cohorts) (www.fda.gov)	Safety/adverse events; dose levels; PK/PD parameters
II	Patients with target disease conditions	Evaluate preliminary efficacy; further evaluate safety and dosing (www.fda.gov)	100s of patients (multiple groups/doses) (www.fda.gov)	Efficacy signals (biomarkers/clinical outcomes); adverse effects
III	Patients with target disease (confirmed by diagnosis)	Confirm efficacy and safety on a large scale; support labeling (www.fda.gov)	Hundreds to several thousands (www.fda.gov)	Clinical efficacy (primary endpoints), safety in diverse patients
IV	Broad real-world patient population	Monitor long-term safety; assess effectiveness, compliance, new uses (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)	Variable (post-marketing studies or registries)	Rare adverse events, long-term outcomes, off-label insights

Table 1. Summary comparison of Clinical Trial Phases I–IV. (Regulatory guidance: FDA/CDER Phase definitions (www.fda.gov); Phase IV as real-world surveillance (pmc.ncbi.nlm.nih.gov).)

Historical Context

The rationale for sequential clinical phases arises from both science and tragedy. In the early 20th century, clinical research was unstructured: therapies often entered practice based on anecdote. The streptomycin trial (1948) and polio vaccine trials (1950s) demonstrated the power of randomized evidence. However, adverse events such as the thalidomide disaster (early 1960s) – where a sedative given to pregnant women caused thousands of birth defects – spotlighted the need for systematic safety and efficacy testing. In response, the 1962 Kefauver–Harris amendments in the U.S. required that manufacturers prove a drug’s effectiveness before marketing through “adequate and well-controlled” trials (pmc.ncbi.nlm.nih.gov). Over ensuing decades, this global shift formalized regulators’ expectation that testing proceeds from small safety studies to large efficacy trials (essentially Phases I–III) before approval is granted. Phase IV arose more informally: once a product is on the market, regulators and sponsors continue to collect data on long-term or rare risks that were not fully captured pre-approval (pmc.ncbi.nlm.nih.gov).

The phases also reflect ethical progression. First-in-human studies, including those in healthy volunteers, require a justified risk–benefit assessment, informed consent, and measures to minimize and manage risk; they are not necessarily minimal-risk research. Later trials in patients may offer the prospect of direct benefit, but still require a favorable risk–benefit assessment. Oversight by Institutional Review Boards (IRBs) and regulatory bodies (FDA, EMA, etc.) helps ensure that each trial phase protects participants through safeguards such as appropriate starting doses, sentinel or staggered dosing when warranted, and monitoring. Modern guidelines such as ICH E6(R3) (Good Clinical Practice), finalized in 2025, codify protections across all phases with a modernized risk-based approach (www.ema.europa.eu).

The Broad Role of Phases in Drug Development

Each phase serves a gatekeeping function, pressing candidate therapies for increasingly stringent evidence. After preclinical (animal/lab) work establishes basic safety and activity, Phase I is the first human test. If Phase I is tolerable and identifies useful dosing, Phase II tests whether the drug likely works in patients. Failure at Phase II often halts a program (lack of efficacy or unacceptable toxicity is common). Succeeding Phase II, a robust Phase III trial is run to “confirm” that efficacy and safety are sufficient for labeling. Only after positive Phase III (and sometimes additional efficacy studies) will a regulatory submission proceed. Even after approval, Phase IV and pharmacovigilance continue to refine the understanding of the drug. Thus, the four-phase model is the framework through which nearly all new drugs (and many biologics) must pass on their path to patients.

Figure 1 (see below) diagrams the typical flow of drug candidates through the phases, including attrition and timelines. The figure highlights that the probability of success declines at each transition. For example, a 2025 analysis of more than 20,000 clinical development programs estimated that only about **28–30%** of Phase II programs proceeded to Phase III in recent time windows, and only about **50–53%** of Phase III programs led to approval ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36888888/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36888888/)). The overall chance that a program entering Phase I reaches the market is often cited at roughly **5–10%**, depending on how programs and molecules are counted ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36888888/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36888888/)). These attrition figures underscore why the drug development process is long, costly, and risky.

Phase I: First-in-Human Studies

Purpose and Design. Phase I trials are the first exposure of humans to an investigational drug, typically following extensive animal safety testing. The primary goal is to characterize safety and tolerability. Dose escalation is common, particularly in oncology, but Phase I dose selection can also be guided by pharmacokinetics, pharmacodynamics, exposure–response data, target engagement, and predefined safety criteria. Regulators expect sponsors to justify the initial human dose (often using the “No Observed Adverse Effect Level” in animals) and to set clear stopping rules (www.ema.europa.eu). Phase I often includes pharmacokinetic (PK) and pharmacodynamic (PD) measurements: how the body handles the drug and how the drug affects biomarkers or physiology. In some cases (e.g. oncology, gene therapies), Phase I may also seek any indication of biological activity (efficacy).

Traditionally, most Phase I trials are conducted in **healthy volunteers**. The logic is to isolate the drug’s basic behavior without confounding disease. Typical Phase I protocols use a “single ascending dose (SAD)” design (one group gets a low dose; if safe, the next group gets a higher dose) followed by a “multiple ascending dose (MAD)” phase where repeated dosing is tested. The total number of subjects in a Phase I study is generally small – often between 20 and 80 participants (www.fda.gov). Table 2 (later) provides typical parameters for reference. The cohort sizes are usually around 4–10 volunteers per dose level. Endpoints are mainly PK parameters (C_{max}, AUC), vital sign changes, lab values, and adverse events. In oncology dose-escalation studies, a maximum tolerated dose may help inform dose selection. In other programs, the dose for later studies is selected using the totality of safety, PK/PD, exposure–response, and pharmacologic evidence.

In some therapeutic areas, **Phase I trials differ in design**. Oncology drugs (especially cytotoxic or targeted anticancer agents) may be given first to cancer patients rather than healthy people, because of the high risk and potential direct benefit. These “first-in-human” oncology trials often enroll patients with advanced, refractory cancers. Such Phase I oncology protocols may combine safety assessment with initial efficacy signals (e.g. tumor response), blurring into Phase II objectives ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)).

Ethical Considerations. Phase I studies raise particular ethical issues. Participants (especially healthy volunteers) derive no therapeutic benefit but face unknown risks ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)). They are often motivated by payment, raising concerns about undue inducement. Research shows Phase I cohorts frequently include disproportionately high numbers of economically disadvantaged minorities ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)), underscoring vulnerabilities. Ethical oversight (IRB review, informed consent, risk minimization) is critical. Contemporary discussions emphasize fair compensation, clear communication of novel risks, and rigorous monitoring to protect these participants ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)).

The 2006 TGN1412 study involved an investigational anti-CD28 monoclonal antibody administered to six healthy volunteers (pubmed.ncbi.nlm.nih.gov). Experience from the study informed subsequent guidance on first-in-human risk assessment and dosing strategies, including the EMA’s revised “First-in-Human” guidance (www.ema.europa.eu).

Implementation and Current Trends. Phase I trials are typically single-center or small multi-center studies. The investigator and sponsor must prepare an Investigational New Drug (IND) or Clinical Trial Application (CTA) submission. Incremental continuation of dosing (e.g. from cohort to cohort) depends on review of accumulating data. Increasingly, designs incorporate modern tools: modeling and simulation (PK/PD models) to optimize dose escalations, biomarkers to de-risk failure, and in some cases accelerated titration (giving more rapid dose increments). There is also a movement toward “Phase 0” or exploratory IND trials with microdosing (truly tiny doses to gather PK data without expecting effect); these are outside the traditional I–IV, but have been explored in oncology (www.slideshare.net).

Case Study – Oncology Phase I. Oncology Phase I trials differ significantly from typical Phase I. An example is a first-in-human study of an oncolytic virus given to patients with advanced solid tumors (see Case 1 below) – illustrating that oncology Phase I can involve severely ill patients. Oncologists often use such trials to assess tolerability and any anti-tumor activity. Success-rate analyses also show that oncology Phase I programs have had lower progression rates to Phase II in recent years ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)). In practice, oncology Phase I protocols may enroll 20–50 patients, escalating doses cautiously. If partial responses are seen at a tolerated dose, that dose may be taken forward into Phase II.

Despite the small scale, Phase I provides critical go/no-go decisions. For example, findings from the TGN1412 trial informed subsequent approaches to first-in-human development (pubmed.ncbi.nlm.nih.gov). Conversely, a clean Phase I safety profile with promising biomarker effects can support expensive Phase II work.

Phase II: Dose-Finding and Proof-of-Concept Studies

Goals and Types. Phase II trials are often called “proof-of-concept” studies. Their aim is to evaluate whether the drug appears to work in patients and to further characterize safety in the target population. These trials provide the first controlled evidence of efficacy, albeit in a limited number of patients. They help answer: “Does

this drug have enough biological effect to justify a large Phase III trial?” and “What dose/regimen is most promising?”

Phase II is sometimes subdivided: **Phase IIa** (pilot studies, maybe uncontrolled or open-label) focused on biological activity, and **Phase IIb** (placebo- or active-controlled dose-ranging studies) focused on determining optimal dosing. For example, several parallel arms might receive different dose levels to select the best candidate dose for Phase III. In any case, Phase II involves *patients* (unlike healthy volunteers) and typically uses intermediate or surrogate endpoints (like tumor shrinkage, viral load reduction, symptom scores) instead of hard clinical outcomes.

Design Considerations. By this point, the design often becomes randomized and sometimes blinded, to reduce bias. Classic Phase II designs include single-arm trials (especially in oncology where tumor reduction can be measured against historical control) or small randomized trials (e.g. drug vs. placebo or dose A vs. dose B). The sample size is usually in the low hundreds, often determined by feasibility rather than full statistical power. However, biostatisticians increasingly use more formal designs: randomized Phase II with power estimates, two-stage designs (stopping early for futility), or adaptive randomization. In oncology, for instance, the “Simon two-stage” design is popular for early signals (stop if insufficient responses).

Key endpoints are chosen to gauge whether larger trials are warranted. Often these are intermediate efficacy measures or composite safety-efficacy scores. Secondary data may include biomarker changes, pharmacodynamics, and detailed adverse event collection. Phase II also refines inclusion/exclusion criteria, methodologies, and feasibility assessments for Phase III plans.

Because Phase II bridges early safety to late confirmatory trials, its failure rate is high. Many drug candidates “fail” at Phase II due to lack of clear efficacy or unacceptable side effects in patients that were not seen in Phase I. One industry report noted “Phase II remains one of the most challenging steps in clinical drug development” ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)), in part because effects there must be large enough to pursue.

Case Study – Single-Arm vs. Randomized Phase II. Historically, many Phase II trials, especially in oncology and rare diseases, have been single-arm (all patients get the drug) and use historical controls for comparison. However, this approach risks false positives due to selection biases. Recent guidance in oncology encourages at least some controls even in Phase II ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)). For example, a Phase II cancer drug trial might randomize patients 2:1 to drug vs. standard-of-care, allowing an internal control and more reliable efficacy estimate before proceeding to Phase III. In non-oncology fields, randomized Phase II is also common. For a new migraine medication, for instance, a Phase II trial might randomize 100 patients to low dose, high dose, or placebo to verify that the doses improve monthly migraine days over placebo.

Phase II in the Regulatory Context. While Phase II trials alone are not sufficient for approval, positive Phase II results can sometimes be used for accelerated pathways. For example, in serious or unmet-need conditions, a strong Phase II outcome might justify a conditional approval with the commitment of further Phase III or Phase IV data. Additionally, “Phase II” trials may include exploratory objectives like identifying biomarkers of response for later trials.

Phase III: Pivotal Confirmatory Trials

Purpose and Scale. Phase III trials are the linchpin of drug development. Their goal is to confirm that a drug is effective and safe for its intended indication in a large, representative patient population. Due to their pivotal nature, Phase III studies are typically *randomized controlled trials (RCTs) with pre-specified primary clinical endpoints (e.g. survival, disease recurrence, symptom improvement rates) that directly support labeling. They usually involve hundreds to thousands of patients across multiple sites (often multinational) to ensure geographic and demographic diversity.

Given their size and cost, Phase III trials are usually funded and organized by pharmaceutical companies and require extensive planning: protocol development, site selection, randomization systems, data monitoring committees for safety, and so on. They must adhere to strict statistical requirements for demonstrating efficacy. For instance, if the primary endpoint is the reduction of HbA1c in diabetes, the trial must show a statistically significant and clinically meaningful improvement over control (usually placebo or existing therapy) at a predetermined alpha (commonly 0.05) and power (80–90%).

Typical Phase III trials compare the new drug to the best available standard of care, or placebo if no standard exists. Many modern Phase III studies are event-driven: they continue until a target number of outcome events (e.g. heart attacks, cancers) occur. Sample size is thus a function of expected effect size and outcome incidence. As a rough guide, cardiovascular outcomes trials enrollment often exceeds 5,000 patients, whereas many Phase III oncology trials enroll 300–1,000. The heterogeneity of modern drug classes means there is wide variability: a rare disease Phase III may only have 100 patients worldwide, whereas a blockbuster indication trial could exceed 10,000.

Success and Failure Modes. Succeeding in Phase III means demonstrating a favorable benefit-risk profile. Regulatory agencies expect that Phase III *primary endpoints* are met in a robust manner. Failure modes include: lack of efficacy (most common), unexpected toxicity, or manufacturing/quality issues. Sometimes a drug that looked promising in Phase II fails in Phase III. For instance, a therapy for Alzheimer's might show cognitive score improvement in small trials but then fail to affect clear endpoints in a large, longer trial. These failures incur huge costs – a single Phase III program can cost hundreds of millions.

Conversely, successful Phase III results allow a company to file for approval. If the data convincingly show safety and efficacy, regulators (like the FDA) may approve the drug for marketing. The companies then present the entire package (Phase I–III data) in an NDA or BLA submission.

Global and Regulatory Variations. Phase III designs often account for global differences. Many Phase III trials are now multinational, enrolling in the US, Europe, Asia, etc., to meet multiple regulatory authorities' requirements in parallel. Regulatory standards are applied to the totality of evidence. FDA has stated that substantial evidence of effectiveness typically consists of two adequate and well-controlled clinical trials, or one adequate and well-controlled trial plus confirmatory evidence when scientifically appropriate. The evidence needed in any application depends on the disease, study design, endpoints, and available confirmatory evidence. Special designations can modify how Phase III is done. Fast Track or Breakthrough designation can allow rolling submissions; Priority Review shortens the FDA review timeline, while Accelerated Approval may rely on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit in serious conditions (e.g. tumor response in some cancers), with confirmatory trials generally required.

Phase III also now often involves advanced elements: *adaptive designs*, where interim analyses may allow changes (e.g. sample size re-estimation); *platform trials* testing multiple therapies under one protocol (e.g. I-SPY in cancer); *noninferiority trials* (showing new drug is not worse than standard by a margin, often used when placebo is unethical); and pragmatic trials that mimic clinical practice settings. For example, in pain management, a pragmatic Phase III trial might use broad inclusion and real-world comparators. All such designs must balance flexibility with pre-specification to avoid bias.

Case Study – COVID-19 Vaccine Trials. A recent high-profile example of Phase III innovation was the development of several COVID-19 vaccines in 2020–21. Under tremendous public health urgency, developers overlapped and accelerated phases. Phase I/II combined safety/immunogenicity in small cohorts was quickly followed by large Phase III RCTs (some enrolling 30,000+ participants) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Regulatory agencies (like FDA) granted Emergency Use authorizations based on Phase III results much faster than normal. Notably, manufacturers like Pfizer-BioNTech and Moderna produced vaccine doses “at risk” before their Phase III trials were complete ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). These trials required tens of thousands of subjects and used primary endpoints of confirmed COVID-19 cases. The success of these trials (showing ~95% efficacy) within 12 months was unprecedented, demonstrating how crisis conditions can compress and accelerate the traditional Phase I–III timeline while still adhering to core principles. ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))

Phase IV: Post-Marketing Surveillance and Beyond

Purpose of Phase IV. After regulatory approval, a new drug enters broader use in the general population.

Phase IV (post-marketing) activities are crucial to monitor the drug’s performance outside the controlled confines of a trial. As one authority notes, “[n]ot all Phase IV studies are PMS but every PMS [post-marketing surveillance] study is a Phase IV study.” In practice, Phase IV encompasses any research conducted after approval, including both observational and interventional studies ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)).

The main objectives are:

- **Long-term Safety Monitoring:** Clinical trials usually involve a few thousand patients at most and relatively short follow-up (often <2 years). Many adverse effects (especially rare events or those arising from chronic use) will only appear after millions have taken the drug. Phase IV pharmacovigilance (spontaneous adverse event reporting, registries) is essential to capture these. For example, serious liver toxicity or cardiac risk might only become evident post-approval. Post-marketing reports and pooled analyses can inform regulatory and sponsor decisions about whether a medicine remains on the market (pubmed.ncbi.nlm.nih.gov) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Continued surveillance is therefore important.
- **Effectiveness in Real World:** There can be a gap between efficacy (performance in trials) and effectiveness (performance in routine practice). Phase IV studies – often non-randomized cohorts or pragmatic trials – assess how a drug works in more diverse, comorbid, or adherent populations. This reflects the commentary that Phase IV is “the real test... the drug is tested in the real world” ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). For instance, a blood pressure drug approved in trials might be studied in Phase IV for long-term outcomes in elderly or pediatric patients.

- **New Indications and Comparative Use:** Phase IV can open new uses. Observational data may suggest benefit in non-approved conditions, leading to formal trials (and possibly supplemental approvals). Sometimes head-to-head trials with competitors are done post-approval. Registries of special populations (e.g. pregnant women, patients with organ failure) are common Phase IV endeavors.
- **Regulatory Commitments:** Regulators may require post-approval studies as a condition of approval – for example, postmarketing requirements (PMRs) in the U.S. or imposed post-authorisation safety or efficacy studies in the EU, sometimes alongside a risk management plan (RMP) in Europe or a REMS in the U.S. These studies might focus narrowly, such as a long-term safety study mandated for a potential carcinogen.

Methods of Phase IV. Unlike pre-approval phases, Phase IV typically involves large observational cohorts, disease registries, and sometimes additional controlled trials. For example, a new epilepsy drug might have a Phase IV registry tracking thousands of patients for seizure control and side effects over years. Passive surveillance (e.g. FDA's FAERS or WHO's VigiBase) collects spontaneous reports of adverse events worldwide. Database studies (insurance or electronic health records) may be used to study drug utilization and outcomes. If still needed, post-approval trials (so-called Phase IV trials) can also be randomized, but often they are less controlled. For instance, many vaccines have Phase IV trials to monitor long-term immunity or rare adverse events in thousands post-licensure.

Crucially, Phase IV “never ends” as long as the product is marketed ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Safety monitoring continues through advertising, scientific publications, and even patient feedback. Electronic systems (like FDA's Sentinel) now proactively mine health records for safety signals.

Implications of Phase IV. Because Phase IV data often prompt label changes, dose adjustments, or usage restrictions, they can be contentious. Pressure to reveal honest post-market findings can clash with commercial interests ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). There have been cases where adverse outcomes in Phase IV prompted lawsuits or black-box warnings. Effective Phase IV relies on transparency (e.g. doctors and patients report adverse events), robust data infrastructure, and independent analysis. Recent innovation includes using “real-world evidence” (RWE) analysts to supplement or sometimes substitute for RCTs, but rigorous methodology remains vital.

Clinical Trial Pathways and Regulatory Context

While the phase framework is global, key differences exist in how it operates under different regulatory regimes. Here we highlight some overarching regulatory considerations:

- **U.S. FDA Regulations:** In the U.S., the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics (CBER) oversee drug trials. Many U.S. drug trials require an IND (Investigational New Drug application), but qualifying clinical investigations of lawfully marketed drugs may be exempt under 21 CFR 312.2. The FDA defines Phase I–III trials and has guidance documents for each stage. The FDA can allow “accelerated” approvals (using surrogate endpoints) in serious diseases, meaning that confirmatory Phase IV studies are needed as a condition ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). FDA has explained that, in appropriate circumstances, one adequate and well-controlled clinical investigation may

be paired with confirmatory evidence to establish substantial evidence of effectiveness; this is not a blanket one-trial rule (**FDA**). The FDA also issued draft guidance in January 2026 on Bayesian methodology for clinical trials, signaling a shift toward more flexible, data-driven trial designs (**Applied Clinical Trials Online**), and finalized guidance on Enhancing Participation in Clinical Trials in December 2025 (**Clinical Leader**). In addition, CBER released draft guidances on innovative trial designs for cell and gene therapy products in small populations (September 2025), and in December 2025 FDA announced that, for certain medical-device submissions, identifiable individual patient data need not always be submitted with real-world evidence; FDA said it intended to consider updating its guidance for drugs and biologics.

- **European Medicines Agency (EMA):** The EMA coordinates drug approval in the EU. Clinical trials must follow the **EU Clinical Trials Regulation (No 536/2014)** and Good Clinical Practice standards. The EMA publishes scientific guidelines including specific advice (e.g. on FIH trial design (www.ema.europa.eu)). The transitional period for migrating all clinical trials from the old Directive to Regulation 536/2014 concluded on January 31, 2025, with all active trials now managed through the Clinical Trial Information System (CTIS). In December 2025, the European Commission proposed the European Biotech Act, which would shorten clinical trial authorization timelines – for example, from 106 to 76 days for multinational trials, and to 47 days where no request for further information is issued – according to legal analyses of the proposal (**Jones Day**). The proposal is not yet law. Conditional marketing authorization in the EU also relies on post-authorization studies.
- **Other Jurisdictions:** Japan (PMDA), Canada (Health Canada), China (NMPA), and others have analogous structures. For example, China has been reforming its approval process, including creating an expedited review pathway; recent analyses show Chinese Phase I trials have historically lower progression rates (as low as 20% in 2016–2020) (pmc.ncbi.nlm.nih.gov), perhaps reflecting different risk approaches or emerging infrastructure.
- **International Harmonization:** ICH guidelines (e.g. E8, E6, E9) provide a common framework. ICH E8 (R1) emphasizes “quality by design” for trials (including all phases) and risk-based approaches. The landmark **ICH E6(R3) revision** was finalized in January 2025 and has been progressively implemented across regions: the EMA adopted it effective July 23, 2025; the FDA released its final guidance in September 2025; and the UK MHRA will make it a legal requirement from April 28, 2026 (**ACRP**). E6(R3) introduces a risk-based, proportionate approach to GCP and is structured as overarching principles, Annex 1 (interventional clinical trials), and Annex 2 (additional considerations for non-traditional interventional clinical trials). Annex 2 reached ICH adoption on June 3, 2026 and CHMP adoption on June 25, 2026; it is scheduled to take effect in the EU on January 15, 2027.
- **Ethics and IRBs:** Regardless of phase, all trials must obtain ethical review and informed consent. Early phases often have added protections (e.g. sentinel dosing or staggered enrolment). The Common Rule (US), Declaration of Helsinki, and local laws apply throughout.

Current Trends and Innovations

Traditional Phase I–III models are evolving. Key current trends include:

- **Adaptive and Seamless Designs:** Trials that adapt in response to interim data are increasingly common. Examples include umbrella and basket trials in oncology, which test multiple drugs or indications under one protocol (e.g. NCI MATCH, Lung-MAP). Some trials combine Phase II and III (a single protocol with an interim look that can lead to expansion to pivotal Phase III enrollment). The COVID-19 vaccine efforts mentioned earlier exemplify this: Phase I/II → interim analysis → immediate transition to an expanded Phase III ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)), all within one rolling development.
- **Decentralized and Digital Trials:** Techniques like telemedicine, remote monitoring devices, and electronic patient-reported outcomes are now integrated at all phases, with over 40% of companies innovating in clinical trials focusing on decentralized trials or real-world evidence generation as of 2025–2026 ([AHA](#)). Wearable biosensors enable safety monitoring outside the clinic, and remote data collection through mobile applications allows participants to engage in studies from their homes. ICH E6(R3) Annex 2 addresses GCP considerations for decentralized and other non-traditional interventional clinical trials. It was adopted in June 2026 and is scheduled to take effect in the EU on January 15, 2027. “Microtrials” or “phase 0” studies, which use very low doses and modern bioanalytics to gather PD data in <10 subjects, continue to be explored in oncology (www.slideshare.net).
- **Personalized Medicine and Biomarkers:** Precision medicine (targeted oncology, genetic disorders) means that even large Phase III trials may rely on biomarker-selected populations. Regulatory guidance now often links trial phase definitions to companion diagnostics (e.g. testing only patients with a mutation). This can shrink Phase II/III sizes but increase complexity.
- **Artificial Intelligence & Trial Optimization:** AI and machine-learning tools are being evaluated and used across clinical-trial operations, including recruitment, data management, and trial planning. Their effects on enrollment, timelines, and costs are context-dependent and should not be assumed from generalized percentage claims. Federated-learning approaches may allow models to be trained across institutions without centrally pooling raw patient data, subject to privacy, validation, and governance requirements. FDA's draft guidance on Bayesian methodology addresses appropriate uses of Bayesian methods in clinical trials of drug and biological products ([FDA draft guidance](#)).
- **Real-World Evidence (RWE):** Regulatory agencies are considering and using real-world evidence in appropriate contexts. In December 2025, FDA announced guidance for certain medical-device submissions under which identifiable individual patient data need not always be submitted with real-world evidence. FDA said it intended to consider updating its guidance for drugs and biologics. Real-world evidence can complement clinical evidence, but its suitability depends on the regulatory question and the quality and relevance of the data.
- **Global and Ethical Shifts:** There is growing emphasis on diversity (ensuring trials represent women, minorities, elderly). For applicable clinical studies, FDA's Diversity Action Plan framework calls for study-specific enrollment goals and a rationale for those goals; it does not impose a universal fixed representation requirement for particular racial or ethnic groups ([FDA](#)). Patient groups have more influence on trial design (patient-focused endpoints).

Case Studies and Real-World Examples

To illustrate these concepts, below are representative case studies from each phase:

- 1. Phase I – TGN1412 and First-in-Human Trial Guidance:** The 2006 TGN1412 Phase I study involved six healthy volunteers and informed later approaches to first-in-human trial oversight (pubmed.ncbi.nlm.nih.gov). Subsequent guidance emphasized risk assessment, sentinel dosing, and monitoring in first-in-human trials.
- 2. Phase II – Alzheimer’s Drug Evolution:** A series of trials of amyloid-targeting drugs (e.g. solanezumab) showed disappointing efficacy, leading companies either to halt programs or require even larger Phase III trials. Aducanumab (Aduhelm) eventually received controversial accelerated approval in 2021 based on amyloid reduction, but Biogen discontinued it in 2024. However, the field advanced significantly: lecanemab (Leqembi) was granted full FDA approval in 2023 after Phase III trials demonstrated modest but statistically significant slowing of cognitive decline, and in 2025 the FDA approved a subcutaneous autoinjector formulation for easier patient administration. Meanwhile, donanemab (Kisunla) received FDA approval in 2024, becoming the second anti-amyloid therapy to demonstrate clinical benefit in Phase III. These cases highlight how Phase II setbacks can ultimately pave the way for refined approaches that succeed in later trials.
- 3. Phase III – KEYTRUDA in Melanoma and Beyond:** In KEYNOTE-006, the PD-1 inhibitor pembrolizumab (Keytruda) was studied in 834 participants with advanced melanoma in a randomized, open-label Phase III trial against ipilimumab—not placebo or chemotherapy. The trial compared two pembrolizumab dosing schedules with ipilimumab and assessed overall survival as a primary outcome ([Robert et al., KEYNOTE-006](#)). This example illustrates how a large randomized active-comparator trial can provide pivotal evidence in oncology.
- 4. Phase IV – Post-Marketing Evidence:** Post-marketing reports and pooled analyses can inform regulatory and sponsor decisions about a medicine’s labeling and market status (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This illustrates how Phase IV evidence can update conclusions reached earlier in development.
- 5. Basket Trials – NCI-MATCH:** NCI-MATCH assigned patients with advanced cancer to treatment arms based on tumor genomic changes. NCI describes the study as a precision-medicine trial with multiple treatment arms; it is not an example of combined Phase I dose escalation and Phase II development ([NCI-MATCH Trial](#)). Basket and platform trials can nevertheless improve efficiency by evaluating multiple biomarker-defined questions within a shared protocol.
- 6. Emergency Use Authorization – COVID-19 Vaccines:** As earlier noted, in 2020 Pfizer-BioNTech, Moderna, and others shifted rapidly through Phases I–III. Preliminary data from Phase I/II mRNA vaccine trials (safety and neutralizing antibody titers) led directly to Phase III trials with 30,000+ participants (pmc.ncbi.nlm.nih.gov). The vaccines showed ~95% efficacy within a few months. This unprecedented acceleration was possible because of prior knowledge of the SARS-CoV spike protein, massive funding (Operation Warp Speed), and rolling regulatory review. It illustrates how external pressures (pandemic) can overlay on the four-phase model.

These examples demonstrate the unity and diversity of how phases function. They also show that real-world events (disease outbreaks, scientific breakthroughs, or tragedies) can prompt adjustments in how phases are implemented.

Data and Analysis

Attrition and Success Rates

Quantifying success rates at each phase has been a major focus for industry analysts. Published reports (e.g. by Biotechnology Innovation Organization, Biomed trackers, etc.) have long documented attrition: historically only ~11% of drugs entering Phase I reached approval. Recent dynamic analyses show changing trends: an analysis of 9,682 molecules (2001–2023) found that overall success (approval) remained low (around **5–12%**, depending on sponsor and time window) ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)). Breaking this down by stage, the drawn conclusions include:

- **Phase I to II (P1SR):** Current estimates put this around 50% (i.e. roughly half of phase I programs progress) ([pmc.ncbi.nlm.nih.gov](#)). This rate has declined over time (it used to be ~70% in the early 2000s, now ~50%), likely because modern Phase I trials incorporate more efficacy and PK/PD scrutiny ([pmc.ncbi.nlm.nih.gov](#)).
- **Phase II to III (P2SR):** This is the lowest transition probability, about 28–30% in recent windows of a 2025 analysis ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)). That analysis (Zhou et al., *Nature Communications*, 2025) describes Phase II as “one of the most challenging steps in clinical drug development” ([pmc.ncbi.nlm.nih.gov](#)). In oncology, it can be even lower.
- **Phase III to Approval (P3SR):** Typically around 50–60%. In Zhou et al.’s 2025 analysis, Phase III success was about 50–53% in the 2011–2020 windows; in oncology it rose from ~37% to ~58% ([pmc.ncbi.nlm.nih.gov](#)). Note, this can vary greatly by therapeutic area (e.g. infectious disease filings have higher success than psychiatric drugs).

The **overall success rate (OSR)** from Phase I to approval is the product of these. Industry-wide, meta-analyses often cite an overall ~8–11% ([pmc.ncbi.nlm.nih.gov](#)) ([pmc.ncbi.nlm.nih.gov](#)). Zhou et al. reported overall success rates of about 9.2–9.8% for top-20 pharmaceutical companies, compared with about 8.0–9.0% for biotech firms ([pmc.ncbi.nlm.nih.gov](#)). In practice, this means around 9 out of 10 compounds fail somewhere along the path. Table 2 (below) summarizes illustrative progression rates (note: these are approximate and vary by source). The data emphasize that failure is the norm, especially in Phase II. Development decisions rely heavily on rigorous criteria to stop trials for futility to conserve resources.

Phase Transition	Estimated Success Rate (Industry Averages)	Notes / Variability
Phase I → Phase II	~50% (recent); historically ~70% (pmc.ncbi.nlm.nih.gov)	Declined over time; oncology Phase I (in patients) success may be lower
Phase II → Phase III	~28–30% (recent) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)	Typically the low point; depends on indication (e.g. higher in pediatrics (pmc.ncbi.nlm.nih.gov))

Phase Transition	Estimated Success Rate (Industry Averages)	Notes / Variability
Phase III → Approval	~50–60% (pmc.ncbi.nlm.nih.gov)	Can be higher in established fields; lower for novel disease areas
Overall (I → Approval)	~8–11% (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)	One source: ~9.2–9.8% for top-20 pharma, ~8.0–9.0% for biotech (pmc.ncbi.nlm.nih.gov), varies by cause

Table 2. Typical progression/success rates between phases in drug development (aggregated from recent analyses ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))). Actual values vary by disease, molecule type, sponsor, and time period. These illustrate that roughly half of drugs move from I → II, fewer from II → III, and about half of Phase III trials yield approval. The net success is often below 10%.

Trial Scale, Cost, and Duration

Each phase has characteristic scope:

- **Phase I:** As noted, tens of participants. These trials are relatively short (often weeks to a few months for all cohorts) because they involve limited dosing. Costs are modest compared to later phases.
- **Phase II:** Hundreds of patients, often across multiple sites. Duration is often 1–2 years (from first patient in to last patient out), depending on the disease. Costs range tens of millions USD.
- **Phase III:** These are the largest and most expensive trials. For example, an oncology Phase III of 500 patients over 3 years, or a cardiovascular trial of 10,000 patients over 5 years, can cost hundreds of millions (one estimate for developing a single new drug, including all phases, is ~\$2.6–2.7 billion ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))), though costs vary substantially by indication, trial design, enrollment, and follow-up requirements. Time from Phase I start to Phase III completion typically spans 6–8 years, though accelerated pathways can shorten this.
- **Phase IV:** Costs and durations vary widely. A mandatory post-market safety study might cost several tens of millions, whereas routine monitoring costs are diffuse.

A detailed data analysis for each phase's typical timeline is beyond this report, but one can find metrics (e.g. median trial lengths on ClinicalTrials.gov, or industry surveys like the Tufts Center for the Study of Drug Development).

Successes by Therapeutic Area

Success rates also depend strongly on indication. Historical data show oncology has one of the lowest overall success rates (often <5% from I to approval) due to complexity, whereas anti-infectives or vaccines can have higher success rates because microbial targets and surrogates (antibodies) are better understood. Zhou et al. report that success rates differ substantially across disease categories ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)). Regulatory priority diseases (HIV, cancer) may get accelerated efforts, but the science is challenging.

Case Studies and Examples

Case 1 – Oncology First-in-Human (Phase I): A published case described a Phase I study of an oncolytic virus (OVV-01) in advanced solid tumors ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)). Although patients had late-stage disease, the study followed standard FIH precautions: dose escalation cohorts, intensive monitoring. This exemplifies Phase I in oncology: first human test of a biologic showing some tumor necrosis in biopsies (PD endpoints) as well as manageable safety profile. It combined objectives of safety and initial efficacy.

Case 2 – HIV combination therapy: Triple-drug antiretroviral therapy became a major advance in 1996, when researchers showed that such regimens could durably suppress HIV replication and reduce the risk of resistance. Early effective regimens included combinations containing a protease inhibitor and two nucleoside reverse transcriptase inhibitors; they illustrate how evidence from clinical studies can transform treatment practice ([NIAID](#)).

Case 3 – Missed Phase II Signals (Cardiology): Cardiovascular development illustrates why Phase II findings must be interpreted cautiously. A promising early signal may not reliably predict outcomes in a larger, longer confirmatory trial, particularly when the early study is not designed to answer the later trial's clinical question. This highlights the importance of adequate controls, endpoint selection, and statistical planning before committing to Phase III.

Case 4 – Phase IV Signal Detection (Diabetes): Rosiglitazone (Avandia), an antidiabetic medicine, was approved on the basis of glycemic-control data. In 2007, Nissen and Wolski published a meta-analysis of 42 randomized controlled trials that reported an association between rosiglitazone and increased myocardial-infarction risk; the analysis was not a BMJ review and did not rely on VAERS. VAERS is a vaccine adverse-event reporting system and is not a source of rosiglitazone safety data. FDA later reevaluated rosiglitazone cardiovascular-risk data and removed its REMS in 2015. This case illustrates that safety questions can be investigated using randomized-trial evidence, observational research, and postmarketing surveillance, each with distinct strengths and limitations ([Nissen and Wolski, NEJM](#)) ([FDA](#)).

Case 5 – Seamless Development (Gene Therapy): Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy was approved by FDA in 2019 under the regular approval pathway. FDA's review states that an ongoing Phase III trial and a completed Phase I trial provided the primary evidence of safety and effectiveness, with additional ongoing trials contributing to the safety database. This program illustrates that development evidence can be integrated across studies and phases ([FDA Summary Basis for Regulatory Action](#)).

Tables: Comparative Phase Characteristics and Milestones

Table 3. Key regulatory and methodological milestones influencing clinical trial phases.

Year	Milestone	Impact on Clinical Trial Phases
1938	U.S. Federal Food, Drug, and Cosmetic Act	Established regulatory authority over drug safety before marketing.

Year	Milestone	Impact on Clinical Trial Phases
1948	First modern RCT (streptomycin for TB)	Demonstrated power of randomization; set stage for Phase III-style trials.
1962	Kefauver–Harris Amendments (U.S.) (pmc.ncbi.nlm.nih.gov)	Mandated proof of efficacy via RCTs; formalized Phase III as approval criterion.
1990	ICH founded (later ICH Guidelines)	International harmonization of trial conduct (leading to GCP E6, etc.).
1992	FDA accelerated-approval final rule (U.S.)	Established procedures for accelerated approval of certain drugs and biologics for serious or life-threatening illnesses, with postmarketing study requirements where applicable.
1997	Food and Drug Administration Modernization Act (FDAMA) (U.S.)	Enacted November 21, 1997; included provisions to expedite development and review of Fast Track drugs.
2012	FDA Safety and Innovation Act (FDASIA)	Strengthened FDA authorities related to drug-shortage reporting and mitigation.
2016	21st Century Cures Act (U.S.)	Encouraged use of real-world evidence (RWE) in decisions (blurring Phase III/IV).
2022	EU Clinical Trial Regulation No. 536/2014 enforcement	Streamlined EU multi-national trial setup (Phase II/III) and transparency via CTIS; transition completed Jan 2025.
2020	U.S. Operation Warp Speed	Massive funding and overlapping Phases I-III for COVID-19 vaccines (pmc.ncbi.nlm.nih.gov).
2025	ICH E6(R3) finalized (Jan); FDA adopts (Sep); EMA adopts (Jul)	Modernized GCP with risk-based approach; supports decentralized and adaptive trial designs across all phases.
2025	EU CTR 536/2014 transition completed (Jan 31)	All EU clinical trials now managed through CTIS; streamlined multinational Phase II/III conduct.
2025	FDA real-world-evidence announcement	For certain medical-device submissions, FDA stated that identifiable individual patient data need not always be submitted with RWE; FDA said it intended to consider updates to drug and biologic guidance.
2026	FDA draft guidance on Bayesian methods	January 2026 draft guidance addresses the appropriate use of Bayesian methodology in clinical trials of drug and biological products.
2025	European Biotech Act proposed (Dec)	Proposes shorter EU trial authorization timelines (e.g. multinational trials from ~106 to ~76 days; 47 days where no information request is issued); not yet adopted.

Table 3. Historical benchmarks shaping clinical trial phases. (Sources: legal texts and historical analyses ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov)) ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov))).

Implications and Future Directions

Current Implications

The four-phase model has ensured that most new therapies are rigorously vetted before reaching patients. However, its high attrition and cost mean only a few blockbuster drugs emerge after massive investment. This reality has several implications:

- **Economic and Investment:** Investors closely watch phase transitions. Each phase completion is a de-risking milestone that can determine a biotech's valuation. The low success rates have given rise to industry-wide benchmarks and efforts to share data (e.g., public trial registries) to improve efficiency.
- **Patient Access:** The sequential phases delay patient access to effective drugs. For deadly diseases, this time lag is critical. Thus, regulators offer accelerated or compassionate pathways (which effectively compress phase requirements) to get therapies to patients sooner, with Phase IV duties to make up for it.
- **Global Health:** The traditional model is resource-intensive, making development of drugs for rare diseases or low-income settings challenging. Some countries (like India and others) have developed adaptive pathways or prioritized orphan drug support. International collaboration (e.g. WHO's prequalification for vaccines) can help expedite Phase II/III in global targets.
- **Transparency and Ethics:** Mandates like trial registration (ClinicalTrials.gov, EU-CTR) and publishing results (ICMJE requirements) have improved accountability across all phases. Ethical demands for diversity, patient involvement, and post-trial access (ensuring trial participants get beneficial therapies) continue to evolve the conduct of Phases I–IV.

Future Directions

Looking ahead, several trends will shape how phases operate:

- **Decentralized/Virtual Trials:** Decentralized trial approaches can use remote visits, at-home sampling, and remote monitoring when appropriate to the protocol. ICH E6(R3) Annex 2 addresses GCP considerations for decentralized and other non-traditional interventional clinical trials; it was adopted in June 2026 and is scheduled to take effect in the EU on January 15, 2027.
- **Data Science and AI:** Machine learning and related methods are being studied and used in clinical research operations and analysis. FDA issued draft guidance on Bayesian methodology in January 2026; it addresses the appropriate use of Bayesian methods in clinical trials of drug and biological products, including uses related to adaptive designs (FDA). The suitability of AI tools, simulations, synthetic controls, or federated learning depends on the research question, data quality, validation, and applicable regulatory requirements.
- **Regenerative Medicine and Gene Therapy:** For one-time treatments (like cell therapies or CRISPR-based cures), the Phase structure may adapt. These often involve combined Phase I/II studies with long follow-up, and unique post-marketing requirements (e.g. patient registries spanning decades).

- **Precision Medicine:** As treatments target smaller subgroups, even late-phase trials can be small (sometimes reducing Phase III counts) and rely more on biomarkers for primary efficacy. The concept of “Phase IV” might extend to real-world validation of companion diagnostic utility.
- **Real-World Evidence (RWE) and Synthetic Controls:** FDA’s December 2025 announcement concerned certain medical-device submissions and stated that FDA would consider real-world evidence without always requiring identifiable individual patient data. FDA said it intended to consider updating its guidance for drugs and biologics. Whether real-world data or an external control is suitable depends on the research question, data quality, and applicable regulatory requirements.
- **Continuous Learning Trials:** New models (like Bayesian adaptive trials) allow learning and adaptation during the trial, potentially collapsing multi-phase questions into small iterative protocols. For example, an adaptive platform could enroll patients in one protocol and “borrow” control data, seamlessly progressing from safety to efficacy questions.
- **Regulatory Evolution:** Regulatory requirements continue to evolve. FDA’s June 2026 revised draft guidance explains circumstances in which one scientifically rigorous adequate and well-controlled investigation plus confirmatory evidence may satisfy the substantial-evidence standard; the guidance is not final and does not establish a blanket one-trial rule. ICH E6(R3) provides a harmonized framework for good clinical practice; Annex 2 is scheduled to take effect in the EU on January 15, 2027 (FDA).

Conclusion

The four-phase clinical trial framework underpins modern drug development, balancing patient safety with society’s need for new therapies. Each phase has distinct scientific aims and challenges, from the first dosing of humans in Phase I to lifelong surveillance in Phase IV. The cumulative evidence from these stages is what gives healthcare providers confidence that medicines will do more good than harm. Over decades, this system has been refined by lessons from successes and failures, technological advances, and evolving ethics.

Our deep dive shows that while the model is robust, it is actively evolving. The 2025–2026 period has included important changes, including implementation of ICH E6(R3) Principles and Annex 1 and the EU’s completed transition to the Clinical Trials Regulation. FDA’s June 2026 revised draft guidance describes circumstances in which one scientifically rigorous adequate and well-controlled investigation, together with confirmatory evidence, may satisfy the substantial-evidence standard; it is not a blanket one-trial default. High costs and long timelines continue to drive innovation in trial design and analysis (FDA). Complex new therapies (e.g. cell/gene therapy, mRNA platforms) and diverse patient needs (e.g. precision oncology, global health threats) demand flexibility. Clinical research is increasingly blurring traditional boundaries – making the “phases” more of a continuum than a strict sequence. Yet the core principle remains: gather increasingly rigorous evidence in humans before and after approval.

For stakeholders – researchers, clinicians, regulators, and patients – understanding the specifics of each phase is crucial. A drug is only as reliable as the trials that tested it. By continuing to refine trial methodology and learning from every phase’s outcomes, medicine advances methodically and safely. The four-phase paradigm may evolve, but its legacy of structured scientific inquiry and patient protection will endure.

References: This report draws on a wide range of sources, including regulatory guidance, peer-reviewed analyses, and industry data. Key citations include FDA and EMA definitions of trial phases (www.fda.gov) (pmc.ncbi.nlm.nih.gov), recent analyses of trial success rates (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), case reports and reviews of notable trials (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and commentaries by clinical research experts (pmc.ncbi.nlm.nih.gov) (www.ema.europa.eu).

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. <https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/small-business-assistance-frequently-asked-questions-drug-development-and-investigational-new-drug>
2. <https://intuitionlabs.ai/articles/cdisc-standards-sdtm-adam-guide>
3. <https://intuitionlabs.ai/articles/real-world-evidence-analysis>
4. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3148611/>
5. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12572394/>
6. <https://www.nature.com/articles/s41467-025-64552-2>
7. <https://www.sciencedirect.com/science/article/pii/S1359644625000042>
8. <https://intuitionlabs.ai/articles/rare-disease-landscape-2025>
9. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7937046/>
10. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3149409/>
11. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8108842/>
12. <https://intuitionlabs.ai/articles/ich-q7-q8-q9-guide>
13. <https://intuitionlabs.ai/articles/ich-e6-r3-gcp-guidelines-2026>
14. <https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline>
15. <https://www.ema.europa.eu/en/news/revised-guideline-first-human-clinical-trials>
16. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9931499/>
17. <https://pubmed.ncbi.nlm.nih.gov/16908486/>
18. <https://www.slideshare.net/slideshow/clinical-trials-phases-0-3/238440415>
19. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8688307/>
20. <https://pubmed.ncbi.nlm.nih.gov/15582059/>
21. <https://pmc.ncbi.nlm.nih.gov/articles/PMC523096/>
22. <https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-draft-guidance-regarding-confirmatory-evidence-clinical-trials>
23. <https://www.appliedclinicaltrialsonline.com/view/fda-issues-draft-guidance-advance-bayesian-methods-clinical-trials>
24. <https://www.clinicalleader.com/doc/fda-issues-final-guidance-on-clinical-trial-participation-what-you-need-to-do-now-0001>
25. <https://intuitionlabs.ai/articles/eu-clinical-trial-regulation-ctr-guide>
26. <https://www.jonesday.com/en/insights/2026/05/the-proposed-european-biotech-act-100-days-on>
27. <https://acrpnnet.org/2026/02/17/ich-e6r3-unpacked-diving-deep-into-the-impacts-of-the-guideline-changes>

28. <https://www.aha.org/aha-center-health-innovation-market-scan/2025-10-21-how-ai-transforming-clinical-trials>
29. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products>
30. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies>
31. <https://www.nejm.org/doi/full/10.1056/NEJMoa1503093>
32. <https://www.cancer.gov/research/infrastructure/clinical-trials/featured/nci-match>
33. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7313751/>
34. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12142144/>
35. <https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development>
36. <https://pubmed.ncbi.nlm.nih.gov/17517853/>
37. <https://www.fda.gov/media/94871/download>
38. <https://www.fda.gov/media/127961/download>
39. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products>

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore [AI enablement](#), [pharma and biotech software development](#), [data engineering and BI](#), and [Veeva services](#). [Contact IntuitionLabs](#) to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: <https://intuitionlabs.ai>

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.